Search
ENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]
Skin-derived ABCB5-positive Mesenchymal Stem cells
go.drugbank.com/drugs/DB17862InvestigationalSkin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).
Synonyms: allo-APZ2-EBGB-13
go.drugbank.com/drugs/DB18387ExperimentalGB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.
PAS-004
go.drugbank.com/drugs/DB18611InvestigationalPAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Bavisant
go.drugbank.com/drugs/DB12299InvestigationalBavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics, Drug Interactions, Attention Deficit Hyperactivity Disorder, and Attention Deficit Disorders With
Fresolimumab
go.drugbank.com/drugs/DB12396InvestigationalFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis
Lumretuzumab
go.drugbank.com/drugs/DB12683InvestigationalLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Anti-CD7 CAR-T
go.drugbank.com/drugs/DB23322InvestigationalCD7 CAR-T is under investigation in clinical trial NCT07117305 (CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation).
Zorecimeran
go.drugbank.com/drugs/DB15843InvestigationalThe CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body.
Vociprotafib
go.drugbank.com/drugs/DB21559InvestigationalThe usage of the INN stem '-protafib' in the name indicates that Vociprotafib is a human protein tyrosine phosphatase (HPTP) inhibitor. … Vociprotafib is under investigation in clinical trial NCT05054725 (Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies).